請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52122
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張明富 | |
dc.contributor.author | Yung-Chun Ko | en |
dc.contributor.author | 柯詠純 | zh_TW |
dc.date.accessioned | 2021-06-15T16:08:17Z | - |
dc.date.available | 2020-09-25 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-19 | |
dc.identifier.citation | 1. Rizzetto, M., M.G. Canese, J.L. Gerin, W.T. London, D.L. Sly, and R.H. Purcell, Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis, 1980. 141(5): p. 590-602. 2. Honda, M., L.H. Ping, R.C. Rijnbrand, E. Amphlett, B. Clarke, D. Rowlands, and S.M. Lemon, Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology, 1996. 222(1): p. 31-42. 3. Holland, J., K. Spindler, F. Horodyski, E. Grabau, S. Nichol, and S. VandePol, Rapid evolution of RNA genomes. Science, 1982. 215(4540): p. 1577-85. 4. Martell, M., J.I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, J. Guardia, and J. Gomez, Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol, 1992. 66(5): p. 3225-9. 5. Cai, Z. and J. Sprent, Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J Exp Med, 1996. 183(5): p. 2247-57. 6. Lai, M.Y., J.H. Kao, P.M. Yang, J.T. Wang, P.J. Chen, K.W. Chan, J.S. Chu, and D.S. Chen, Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology, 1996. 111(5): p. 1307-12. 7. Fung, A., Z. Jin, N. Dyatkina, G. Wang, L. Beigelman, and J. Deval, Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother, 2014. 58(7): p. 3636-45. 8. Li, H.C. and S.Y. Lo, Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol, 2015. 7(10): p. 1377-89. 9. Wasley, A. and M.J. Alter, Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis, 2000. 20(1): p. 1-16. 10. Gumber, S.C. and S. Chopra, Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med, 1995. 123(8): p. 615-20. 11. Lonardo, A., L.E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C.P. Day, Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology, 2004. 126(2): p. 586-97. 12. Chen, H.F., C.Y. Li, P. Chen, T.T. See, and H.Y. Lee, Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc, 2006. 69(4): p. 146-52. 13. Mehta, S.H., F.L. Brancati, M.S. Sulkowski, S.A. Strathdee, M. Szklo, and D.L. Thomas, Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med, 2000. 133(8): p. 592-9. 14. Koike, K., Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res, 2005. 33(2): p. 145-50. 15. Kaito, M., S. Watanabe, K. Tsukiyama-Kohara, K. Yamaguchi, Y. Kobayashi, M. Konishi, M. Yokoi, S. Ishida, S. Suzuki, and M. Kohara, Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol, 1994. 75 ( Pt 7): p. 1755-60. 16. Choo, Q.L., K.H. Richman, J.H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, R. Medina-Selby, P.J. Barr, and et al., Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A, 1991. 88(6): p. 2451-5. 17. Al Naamani, K., S. Al Sinani, and M. Deschenes, Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol, 2013. 27(1): p. e8-12. 18. Chen, P.J., M.H. Lin, K.F. Tai, P.C. Liu, C.J. Lin, and D.S. Chen, The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. Virology, 1992. 188(1): p. 102-13. 19. Alter, M.J., Epidemiology of hepatitis C virus infection. World J Gastroenterol, 2007. 13(17): p. 2436-41. 20. Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I., Hepatitis C virus infection: molecular pathways to insulin resistance. J Virol, 2011. 8: p.474-479. 21. Bukh, J., R.H. Purcell, and R.H. Miller, Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A, 1992. 89(11): p. 4942-6. 22. Otto, G.A. and J.D. Puglisi, The pathway of HCV IRES-mediated translation initiation. Cell, 2004. 119(3): p. 369-80. 23. Jopling, C.L., M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow, Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005. 309(5740): p. 1577-81. 24. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama, Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol, 1991. 65(3): p. 1105-13. 25. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, and K. Shimotohno, Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A, 1991. 88(13): p. 5547-51. 26. Lin, C., J.A. Thomson, and C.M. Rice, A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol, 1995. 69(7): p. 4373-80. 27. Mizushima, H., M. Hijikata, S. Asabe, M. Hirota, K. Kimura, and K. Shimotohno, Two hepatitis C virus glycoprotein E2 products with different C termini. J Virol, 1994. 68(10): p. 6215-22. 28. Mizushima, H., M. Hijikata, Y. Tanji, K. Kimura, and K. Shimotohno, Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2. J Virol, 1994. 68(4): p. 2731-4. 29. Levrero, M., Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene, 2006. 25(27): p. 3834-47. 30. Hijikata, M., H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi, N. Kato, T. Tanaka, K. Kimura, and K. Shimotohno, Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol, 1993. 67(8): p. 4665-75. 31. Manabe, S., I. Fuke, O. Tanishita, C. Kaji, Y. Gomi, S. Yoshida, C. Mori, A. Takamizawa, I. Yosida, and H. Okayama, Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. Virology, 1994. 198(2): p. 636-44. 32. Boulant, S., R. Montserret, R.G. Hope, M. Ratinier, P. Targett-Adams, J.P. Lavergne, F. Penin, and J. McLauchlan, Structural determinants that target the hepatitis C virus core protein to lipid droplets. J Biol Chem, 2006. 281(31): p. 22236-47. 33. Santolini, E., G. Migliaccio, and N. La Monica, Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol, 1994. 68(6): p. 3631-41. 34. Dubuisson, J., F. Penin, and D. Moradpour, Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol, 2002. 12(11): p. 517-23. 35. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, and K. Shimotohno, Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun, 1991. 175(1): p. 220-8. 36. Weiner, A.J., C. Christopherson, J.E. Hall, F. Bonino, G. Saracco, M.R. Brunetto, K. Crawford, C.D. Marion, K.A. Crawford, S. Venkatakrishna, and et al., Sequence variation in hepatitis C viral isolates. J Hepatol, 1991. 13 Suppl 4: p. S6-14. 37. Carrere-Kremer, S., C. Montpellier-Pala, L. Cocquerel, C. Wychowski, F. Penin, and J. Dubuisson, Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol, 2002. 76(8): p. 3720-30. 38. Sakai, A., M.S. Claire, K. Faulk, S. Govindarajan, S.U. Emerson, R.H. Purcell, and J. Bukh, The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A, 2003. 100(20): p. 11646-51. 39. Griffin, S.D., L.P. Beales, D.S. Clarke, O. Worsfold, S.D. Evans, J. Jaeger, M.P. Harris, and D.J. Rowlands, The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett, 2003. 535(1-3): p. 34-8. 40. Pavlovic, D., D.C. Neville, O. Argaud, B. Blumberg, R.A. Dwek, W.B. Fischer, and N. Zitzmann, The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A, 2003. 100(10): p. 6104-8. 41. Grakoui, A., D.W. McCourt, C. Wychowski, S.M. Feinstone, and C.M. Rice, A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A, 1993. 90(22): p. 10583-7. 42. Levin, M.K., M. Gurjar, and S.S. Patel, A Brownian motor mechanism of translocation and strand separation by hepatitis C virus helicase. Nat Struct Mol Biol, 2005. 12(5): p. 429-35. 43. Serebrov, V. and A.M. Pyle, Periodic cycles of RNA unwinding and pausing by hepatitis C virus NS3 helicase. Nature, 2004. 430(6998): p. 476-80. 44. Paeshuyse, J., A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts, The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 2006. 43(4): p. 761-70. 45. Wolk, B., D. Sansonno, H.G. Krausslich, F. Dammacco, C.M. Rice, H.E. Blum, and D. Moradpour, Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol, 2000. 74(5): p. 2293-304. 46. Egger, D., B. Wolk, R. Gosert, L. Bianchi, H.E. Blum, D. Moradpour, and K. Bienz, Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol, 2002. 76(12): p. 5974-84. 47. Yu, G.Y., K.J. Lee, L. Gao, and M.M. Lai, Palmitoylation and polymerization of hepatitis C virus NS4B protein. J Virol, 2006. 80(12): p. 6013-23. 48. Quintavalle, M., S. Sambucini, C. Di Pietro, R. De Francesco, and P. Neddermann, The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J Virol, 2006. 80(22): p. 11305-12. 49. Asabe, S.I., Y. Tanji, S. Satoh, T. Kaneko, K. Kimura, and K. Shimotohno, The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. J Virol, 1997. 71(1): p. 790-6. 50. Reed, K.E., A.E. Gorbalenya, and C.M. Rice, The NS5A/NS5 proteins of viruses from three genera of the family flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol, 1998. 72(7): p. 6199-206. 51. Penin, F., V. Brass, N. Appel, S. Ramboarina, R. Montserret, D. Ficheux, H.E. Blum, R. Bartenschlager, and D. Moradpour, Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem, 2004. 279(39): p. 40835-43. 52. Huang, L., J. Hwang, S.D. Sharma, M.R. Hargittai, Y. Chen, J.J. Arnold, K.D. Raney, and C.E. Cameron, Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem, 2005. 280(43): p. 36417-28. 53. Gale, M.J., Jr., M.J. Korth, N.M. Tang, S.L. Tan, D.A. Hopkins, T.E. Dever, S.J. Polyak, D.R. Gretch, and M.G. Katze, Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology, 1997. 230(2): p. 217-27. 54. Tan, S.L. and M.G. Katze, How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology, 2001. 284(1): p. 1-12. 55. Tellinghuisen, T.L., K.L. Foss, and J. Treadaway, Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog, 2008. 4(3): p. e1000032. 56. Poch, O., I. Sauvaget, M. Delarue, and N. Tordo, Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J, 1989. 8(12): p. 3867-74. 57. Ago, H., T. Adachi, A. Yoshida, M. Yamamoto, N. Habuka, K. Yatsunami, and M. Miyano, Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure, 1999. 7(11): p. 1417-26. 58. Cheng, J.C., M.F. Chang, and S.C. Chang, Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. J Virol, 1999. 73(8): p. 7044-9. 59. Branch, A.D., D.D. Stump, J.A. Gutierrez, F. Eng, and J.L. Walewski, The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis, 2005. 25(1): p. 105-17. 60. Kolykhalov, A.A., S.M. Feinstone, and C.M. Rice, Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol, 1996. 70(6): p. 3363-71. 61. Tanaka, T., N. Kato, M.J. Cho, K. Sugiyama, and K. Shimotohno, Structure of the 3' terminus of the hepatitis C virus genome. J Virol, 1996. 70(5): p. 3307-12. 62. Ito, T. and M.M. Lai, An internal polypyrimidine-tract-binding protein-binding site in the hepatitis C virus RNA attenuates translation, which is relieved by the 3'-untranslated sequence. Virology, 1999. 254(2): p. 288-96. 63. Ito, T., S.M. Tahara, and M.M. Lai, The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J Virol, 1998. 72(11): p. 8789-96. 64. Friebe, P. and R. Bartenschlager, Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication. J Virol, 2002. 76(11): p. 5326-38. 65. Yanagi, M., M. St Claire, S.U. Emerson, R.H. Purcell, and J. Bukh, In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A, 1999. 96(5): p. 2291-5. 66. You, S., D.D. Stump, A.D. Branch, and C.M. Rice, A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol, 2004. 78(3): p. 1352-66. 67. Pereira, A.A. and I.M. Jacobson, New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol, 2009. 6(7): p. 403-11. 68. Agnello, V., G. Abel, M. Elfahal, G.B. Knight, and Q.X. Zhang, Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A, 1999. 96(22): p. 12766-71. 69. Barth, H., E.K. Schnober, F. Zhang, R.J. Linhardt, E. Depla, B. Boson, F.L. Cosset, A.H. Patel, H.E. Blum, and T.F. Baumert, Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol, 2006. 80(21): p. 10579-90. 70. Scarselli, E., H. Ansuini, R. Cerino, R.M. Roccasecca, S. Acali, G. Filocamo, C. Traboni, A. Nicosia, R. Cortese, and A. Vitelli, The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J, 2002. 21(19): p. 5017-25. 71. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A.J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani, Binding of hepatitis C virus to CD81. Science, 1998. 282(5390): p. 938-41. 72. Evans, M.J., T. von Hahn, D.M. Tscherne, A.J. Syder, M. Panis, B. Wolk, T. Hatziioannou, J.A. McKeating, P.D. Bieniasz, and C.M. Rice, Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007. 446(7137): p. 801-5. 73. Liu, S., W. Yang, L. Shen, J.R. Turner, C.B. Coyne, and T. Wang, Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol, 2009. 83(4): p. 2011-4. 74. Blanchard, E., S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C. Wychowski, and Y. Rouille, Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol, 2006. 80(14): p. 6964-72. 75. Tscherne, D.M., C.T. Jones, M.J. Evans, B.D. Lindenbach, J.A. McKeating, and C.M. Rice, Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol, 2006. 80(4): p. 1734-41. 76. Mackenzie, J., Wrapping things up about virus RNA replication. Traffic, 2005. 6(11): p. 967-77. 77. Roingeard, P. and C. Hourioux, Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat, 2008. 15(3): p. 157-64. 78. Andre, P., G. Perlemuter, A. Budkowska, C. Brechot, and V. Lotteau, Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis, 2005. 25(1): p. 93-104. 79. Xiao, B., J.R. Wilson, and S.J. Gamblin, SET domains and histone methylation. Curr Opin Struct Biol, 2003. 13(6): p. 699-705. 80. Liu, Y., W. Chen, J. Gaudet, M.D. Cheney, L. Roudaia, T. Cierpicki, R.C. Klet, K. Hartman, T.M. Laue, N.A. Speck, and J.H. Bushweller, Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell, 2007. 11(6): p. 483-97. 81. Ng, H.H., F. Robert, R.A. Young, and K. Struhl, Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol Cell, 2003. 11(3): p. 709-19. 82. Li, J., D. Moazed, and S.P. Gygi, Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation. J Biol Chem, 2002. 277(51): p. 49383-8. 83. Tachibana, M., K. Sugimoto, T. Fukushima, and Y. Shinkai, Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem, 2001. 276(27): p. 25309-17. 84. Kwon, T., J.H. Chang, E. Kwak, C.W. Lee, A. Joachimiak, Y.C. Kim, J. Lee, and Y. Cho, Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J, 2003. 22(2): p. 292-303. 85. Hamamoto, R., Y. Furukawa, M. Morita, Y. Iimura, F.P. Silva, M. Li, R. Yagyu, and Y. Nakamura, SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol, 2004. 6(8): p. 731-40. 86. Brown, M.A., R.J. Sims, 3rd, P.D. Gottlieb, and P.W. Tucker, Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer, 2006. 5: p. 26. 87. Gross, C.T. and W. McGinnis, DEAF-1, a novel protein that binds an essential region in a Deformed response element. EMBO J, 1996. 15(8): p. 1961-70. 88. Veraksa, A., J. Kennison, and W. McGinnis, DEAF-1 function is essential for the early embryonic development of Drosophila. Genesis, 2002. 33(2): p. 67-76. 89. Spadaccini, R., H. Perrin, M.J. Bottomley, S. Ansieau, and M. Sattler, Structure and functional analysis of the MYND domain. J Mol Biol, 2006. 358(2): p. 498-508. 90. Gottlieb, P.D., S.A. Pierce, R.J. Sims, H. Yamagishi, E.K. Weihe, J.V. Harriss, S.D. Maika, W.A. Kuziel, H.L. King, E.N. Olson, O. Nakagawa, and D. Srivastava, Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet, 2002. 31(1): p. 25-32. 91. Tan, X., J. Rotllant, H. Li, P. De Deyne, and S.J. Du, SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc Natl Acad Sci U S A, 2006. 103(8): p. 2713-8. 92. Kawamura, S., E. Yoshigai, S. Kuhara, and K. Tashiro, smyd1 and smyd2 are expressed in muscle tissue in Xenopus laevis. Cytotechnology, 2008. 57(2): p. 161-8. 93. Diehl, F., M.A. Brown, M.J. van Amerongen, T. Novoyatleva, A. Wietelmann, J. Harriss, F. Ferrazzi, T. Bottger, R.P. Harvey, P.W. Tucker, and F.B. Engel, Cardiac deletion of Smyd2 is dispensable for mouse heart development. PLoS One, 2010. 5(3): p. e9748. 94. Thompson, E.C. and A.A. Travers, A Drosophila Smyd4 homologue is a muscle-specific transcriptional modulator involved in development. PLoS One, 2008. 3(8): p. e3008. 95. Abu-Farha, M., J.P. Lambert, A.S. Al-Madhoun, F. Elisma, I.S. Skerjanc, and D. Figeys, The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics, 2008. 7(3): p. 560-72. 96. Huang, J., L. Perez-Burgos, B.J. Placek, R. Sengupta, M. Richter, J.A. Dorsey, S. Kubicek, S. Opravil, T. Jenuwein, and S.L. Berger, Repression of p53 activity by Smyd2-mediated methylation. Nature, 2006. 444(7119): p. 629-32. 97. Kunizaki, M., R. Hamamoto, F.P. Silva, K. Yamaguchi, T. Nagayasu, M. Shibuya, Y. Nakamura, and Y. Furukawa, The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res, 2007. 67(22): p. 10759-65. 98. Hamamoto, R., F.P. Silva, M. Tsuge, T. Nishidate, T. Katagiri, Y. Nakamura, and Y. Furukawa, Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci, 2006. 97(2): p. 113-8. 99. Liu, C., C. Wang, K. Wang, L. Liu, Q. Shen, K. Yan, X. Sun, J. Chen, J. Liu, H. Ren, H. Liu, Z. Xu, S. Hu, D. Xu, and Y. Fan, SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J Natl Cancer Inst, 2013. 105(22): p. 1719-28. 100. Vieira, F.Q., P. Costa-Pinheiro, D. Almeida-Rios, I. Graca, S. Monteiro-Reis, S. Simoes-Sousa, I. Carneiro, E.J. Sousa, M.I. Godinho, F. Baltazar, R. Henrique, and C. Jeronimo, SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget, 2015. 6(15): p. 13644-57. 101. Wang, S.Z., X.G. Luo, J. Shen, J.N. Zou, Y.H. Lu, and T. Xi, Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro. BMB Rep, 2008. 41(4): p. 294-9. 102. Ren, T.N., J.S. Wang, Y.M. He, C.L. Xu, S.Z. Wang, and T. Xi, Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells. Med Oncol, 2011. 28 Suppl 1: p. S91-8. 103. Chen, L.B., J.Y. Xu, Z. Yang, and G.B. Wang, Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol, 2007. 13(43): p. 5718-24. 104. Foreman, K.W., M. Brown, F. Park, S. Emtage, J. Harriss, C. Das, L. Zhu, A. Crew, L. Arnold, S. Shaaban, and P. Tucker, Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One, 2011. 6(7): p. e22290. 105. Sirinupong, N., J. Brunzelle, E. Doko, and Z. Yang, Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3. J Mol Biol, 2011. 406(1): p. 149-59. 106. Xu, S., J. Wu, B. Sun, C. Zhong, and J. Ding, Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Res, 2011. 39(10): p. 4438-49. 107. Silva, F.P., R. Hamamoto, M. Kunizaki, M. Tsuge, Y. Nakamura, and Y. Furukawa, Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene, 2008. 27(19): p. 2686-92. 108. Van Aller, G.S., N. Reynoird, O. Barbash, M. Huddleston, S. Liu, A.F. Zmoos, P. McDevitt, R. Sinnamon, B. Le, G. Mas, R. Annan, J. Sage, B.A. Garcia, P.J. Tummino, O. Gozani, and R.G. Kruger, Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics, 2012. 7(4): p. 340-3. 109. Mazur, P.K., N. Reynoird, P. Khatri, P.W. Jansen, A.W. Wilkinson, S. Liu, O. Barbash, G.S. Van Aller, M. Huddleston, D. Dhanak, P.J. Tummino, R.G. Kruger, B.A. Garcia, A.J. Butte, M. Vermeulen, J. Sage, and O. Gozani, SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature, 2014. 510(7504): p. 283-7. 110. Raman, M., W. Chen, and M.H. Cobb, Differential regulation and properties of MAPKs. Oncogene, 2007. 26(22): p. 3100-12. 111. Chen, Z., T.B. Gibson, F. Robinson, L. Silvestro, G. Pearson, B. Xu, A. Wright, C. Vanderbilt, and M.H. Cobb, MAP kinases. Chem Rev, 2001. 101(8): p. 2449-76. 112. Cobb, M.H. and E.J. Goldsmith, How MAP kinases are regulated. J Biol Chem, 1995. 270(25): p. 14843-6. 113. Weston, C.R. and R.J. Davis, The JNK signal transduction pathway. Curr Opin Genet Dev, 2002. 12(1): p. 14-21. 114. Karin, M. and E. Gallagher, From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life, 2005. 57(4-5): p. 283-95. 115. Cuenda, A. and S. Rousseau, p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta, 2007. 1773(8): p. 1358-75. 116. Camps, M., A. Nichols, and S. Arkinstall, Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J, 2000. 14(1): p. 6-16. 117. Alonso, A., J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, and T. Mustelin, Protein tyrosine phosphatases in the human genome. Cell, 2004. 117(6): p. 699-711. 118. Wu, J.J., L. Zhang, and A.M. Bennett, The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol Cell Biol, 2005. 25(11): p. 4792-803. 119. Slack, D.N., O.M. Seternes, M. Gabrielsen, and S.M. Keyse, Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J Biol Chem, 2001. 276(19): p. 16491-500. 120. Hutter, D., P. Chen, J. Barnes, and Y. Liu, Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation. Biochem J, 2000. 352 Pt 1: p. 155-63. 121. Charles, C.H., A.S. Abler, and L.F. Lau, cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene, 1992. 7(1): p. 187-90. 122. Guan, K.L. and E. Butch, Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J Biol Chem, 1995. 270(13): p. 7197-203. 123. Franklin, C.C., S. Srikanth, and A.S. Kraft, Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A, 1998. 95(6): p. 3014-9. 124. Sun, H., C.H. Charles, L.F. Lau, and N.K. Tonks, MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell, 1993. 75(3): p. 487-93. 125. Cho, I.J., N.R. Woo, and S.G. Kim, The identification of C/EBPbeta as a transcription factor necessary for the induction of MAPK phosphatase-1 by toll-like receptor-4 ligand. Arch Biochem Biophys, 2008. 479(1): p. 88-96. 126. Kuwano, Y., H.H. Kim, K. Abdelmohsen, R. Pullmann, Jr., J.L. Martindale, X. Yang, and M. Gorospe, MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol, 2008. 28(14): p. 4562-75. 127. Emmons, J., W.H. Townley-Tilson, K.M. Deleault, S.J. Skinner, R.H. Gross, M.L. Whitfield, and S.A. Brooks, Identification of TTP mRNA targets in human dendritic cells reveals TTP as a critical regulator of dendritic cell maturation. RNA, 2008. 14(5): p. 888-902. 128. Brondello, J.M., J. Pouyssegur, and F.R. McKenzie, Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science, 1999. 286(5449): p. 2514-7. 129. Lin, Y.W. and J.L. Yang, Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J Biol Chem, 2006. 281(2): p. 915-26. 130. Lin, Y.W., S.M. Chuang, and J.L. Yang, ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem, 2003. 278(24): p. 21534-41. 131. Cao, W., C. Bao, E. Padalko, and C.J. Lowenstein, Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med, 2008. 205(6): p. 1491-503. 132. Dean, J.L., G. Sully, A.R. Clark, and J. Saklatvala, The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal, 2004. 16(10): p. 1113-21. 133. Ryser, S., A. Massiha, I. Piuz, and W. Schlegel, Stimulated initiation of mitogen-activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the synergistic action of multiple cis-acting elements in the proximal promoter. Biochem J, 2004. 378(Pt 2): p. 473-84. 134. Wang, J., H.R. Ford, and A.V. Grishin, NF-kappaB-mediated expression of MAPK phosphatase-1 is an early step in desensitization to TLR ligands in enterocytes. Mucosal Immunol, 2010. 3(5): p. 523-34. 135. Gil-Araujo, B., M.V. Toledo Lobo, M. Gutierrez-Salmeron, J. Gutierrez-Pitalua, S. Ropero, J.C. Angulo, A. Chiloeches, and M. Lasa, Dual specificity phosphatase 1 expression inversely correlates with NF-kappaB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol Oncol, 2014. 8(1): p. 27-38. 136. Loda, M., P. Capodieci, R. Mishra, H. Yao, C. Corless, W. Grigioni, Y. Wang, C. Magi-Galluzzi, and P.J. Stork, Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol, 1996. 149(5): p. 1553-64. 137. Wu, S.C., S.C. Chang, H.Y. Wu, P.J. Liao, and M.F. Chang, Hepatitis C virus NS5A protein down-regulates the expression of spindle gene Aspm through PKR-p38 signaling pathway. J Biol Chem, 2008. 283(43): p. 29396-404. 138. Pichlmair, A., K. Kandasamy, G. Alvisi, O. Mulhern, R. Sacco, M. Habjan, M. Binder, A. Stefanovic, C.A. Eberle, A. Goncalves, T. Burckstummer, A.C. Muller, A. Fauster, C. Holze, K. Lindsten, S. Goodbourn, G. Kochs, F. Weber, R. Bartenschlager, A.G. Bowie, K.L. Bennett, J. Colinge, and G. Superti-Furga, Viral immune modulators perturb the human molecular network by common and unique strategies. Nature, 2012. 487(7408): p. 486-90. 139. de Chassey, B., V. Navratil, L. Tafforeau, M.S. Hiet, A. Aublin-Gex, S. Agaugue, G. Meiffren, F. Pradezynski, B.F. Faria, T. Chantier, M. Le Breton, J. Pellet, N. Davoust, P.E. Mangeot, A. Chaboud, F. Penin, Y. Jacob, P.O. Vidalain, M. Vidal, P. Andre, C. Rabourdin-Combe, and V. Lotteau, Hepatitis C virus infection protein network. Mol Syst Biol, 2008. 4: p. 230. 140. Gosert, R., D. Egger, V. Lohmann, R. Bartenschlager, H.E. Blum, K. Bienz, and D. Moradpour, Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol, 2003. 77(9): p. 5487-92. 141. Eberle, C.A., M. Zayas, A. Stukalov, A. Pichlmair, G. Alvisi, A.C. Muller, K.L. Bennett, R. Bartenschlager, and G. Superti-Furga, The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. Virology, 2014. 462-463: p. 34-41. 142. Tanji, Y., T. Kaneko, S. Satoh, and K. Shimotohno, Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol, 1995. 69(7): p. 3980-6. 143. Brown, M.A., K. Foreman, J. Harriss, C. Das, L. Zhu, M. Edwards, S. Shaaban, and H. Tucker, C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis. Oncotarget, 2015. 6(6): p. 4005-19. 144. Cordek, D.G., J.T. Bechtel, A.T. Maynard, W.M. Kazmierski, and C.E. Cameron, Targeting the Ns5a Protein of Hcv: An Emerging Option. Drugs Future, 2011. 36(9): p. 691-711. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52122 | - |
dc.description.abstract | C型肝炎病毒是造成嚴重肝疾病的主要病毒之一。近期研究指出C型肝炎病毒感染可能會造成基因體不穩定,而基因體或表觀基因體平衡改變可能導致肝癌的發生。C型肝炎病毒的致癌蛋白質NS5A會引發染色體不穩定,影響細胞的生長及訊息傳遞。在與NS5A結合的蛋白質資料庫中,發現一個組蛋白甲基轉移酶SMYD3會與NS5A蛋白質結合。過去研究指出SMYD3蛋白質在肝癌等癌症組織及細胞中有過量表現的現象。SMYD3具有H3K4及H4K20三甲基化的酵素活性,分別扮演轉錄活化與抑制的角色。在本研究中發現,SMYD3蛋白質在細胞內的分布情形會因NS5A蛋白質存在而改變。在C型肝炎病毒subgenomic replicon HCVR細胞發現NS5A蛋白質與SMYD3蛋白質會在細胞核周圍有共位現象,以免疫共沉澱法證實SMYD3與NS5A蛋白質於細胞質中有交互作用。為探討SMYD3蛋白質與NS5A蛋白質交互作用的重要片段,本研究利用大腸桿菌表現多個不同片段且帶有His-tag的SMYD3蛋白質,將其與HCVR細胞蛋白質進行pull-down分析,結果發現MYND domain及第二個SET domain可能是負責與NS5A蛋白質交互作用的區域。基因序列分析顯示,在dusp1基因啟動子上有多個SMYD3蛋白質結合序列5’-CCCTCC-3’及5’-GGAGGG-3’,本研究利用ChIP assay證明SMYD3蛋白質會結合在dusp1啟動子(-107~+76)上。knockdown實驗也發現,SMYD3蛋白質在調控dusp1基因表現上扮演抑制的角色。當NS5A蛋白質存在時,會降低SMYD3蛋白質結合到dusp1啟動子的能力。本研究結果發現,dusp1基因為SMYD3蛋白質的目標基因,且NS5A蛋白質與SMYD3蛋白質之間的交互作用會降低SMYD3蛋白質對於dusp1基因的抑制效果,造成dusp1基因表現量上升。 | zh_TW |
dc.description.abstract | Hepatitis C virus (HCV) is a major cause of serious liver disease worldwide. HCV infection induces genome instability, leading to further genetic and epigenetic alterations which contribute to the full development of hepatocellular carcinoma. The viral oncoprotein NS5A is likely to be involved in the induction of genome instability and in dysregulating cellular control of growth and signal transduction. Proteomics study revealed a potential interaction of the NS5A protein with the epigenetic factor SMYD3 (SET and MYND domain containing protein 3), a histone methyltransferase. SMYD3 is over-expressed in several cancers including hepatocellular carcinoma. In addition, SMYD3 has histone 3-lysine 4 (H3K4) and histone 4-lysine 20 (H4K20) histone methyltransferase activities that function as transcriptional activator and repressor, respectively. In this study, subcellular localization of endogenous SMYD3 in the presence of NS5A was examined. SMYD3 were mainly colocalized with NS5A at the perinucleus foci in HCV subgenomic replicon HCVR cells. To further analyze which domains of SMYD3 are responsible for interacting with NS5A, various His-tagged truncated SMYD3 protein were ecxpressed and subjected to pull-down analysis with HCVR cell lysates. Results demonstrated involvement of that the MYND domain and the second SET domain in the interaction of SMYD3 with NS5A. Biological significance of the interaction was further studied. Sequence analysis identified several putative SMYD3 binding motifs, 5’-CCCTCC-3’ and 5’-GGAGGG-3’, in the promoter region of dusp1. ChIP assay further demonstrated the binding of SMYD3 to the dusp1 promoter (-107~+76). In addition, NS5A reduced the ability of SMYD3 in binding to dusp1 promoter. Knocked-down experiment indicated a negative role of SMYD3 in regulating dusp1 expression. Taken together, these results indicate that dusp1 is a target gene of SMYD3 and the interaction between NS5A and SMYD3 can reduce the repression function of SMYD3 on dusp1 expression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:08:17Z (GMT). No. of bitstreams: 1 ntu-104-R02442013-1.pdf: 1728601 bytes, checksum: b8bd0afbcebe8485f16b1b94c54f94ef (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要..................................................I 英文摘要.................................................II 縮寫表.................................................IV 緒論......................................................1 實驗材料來源.............................................17 實驗方法.................................................23 實驗結果.................................................41 討論.....................................................48 圖表.....................................................52 參考文獻.................................................67 | |
dc.language.iso | zh-TW | |
dc.title | C型肝炎病毒非結構性蛋白質NS5A透過組蛋白甲基轉移酶SMYD3調控dusp1基因之表現 | zh_TW |
dc.title | Hepatitis C Virus NS5A Protein Regulates the Expression of dusp1 Gene via Histone Methyltransferase SMYD3 | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李明學,歐展言,余明俊 | |
dc.subject.keyword | C型肝炎病毒,非結構性蛋白質NS5A,組蛋白甲基轉移?SMYD3,dusp1基因, | zh_TW |
dc.subject.keyword | hepatitis C virus,NS5A,SMYD3,dusp1, | en |
dc.relation.page | 80 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。